Bevacizumab

(Avastin®)

Avastin®

Drug updated on 9/13/2023

Dosage FormInjection (intravenous; 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL))
Drug ClassVascular endothelial growth factor inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Metastatic colorectal cancer, in combination with intravenous fluorouracilbased chemotherapy for first- or second-line treatment.
  • Metastatic colorectal cancer, in combination with fluoropyrimidineirinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
  • Recurrent glioblastoma in adults.
  • Metastatic renal cell carcinoma in combination with interferon alfa.
  • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinumsensitive recurrent disease.
  • Hepatocellular Carcinoma (HCC): in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Avastin (bevacizumab) Prescribing Information.2022Genentech, Inc. South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of bevacizumab for treating glioblastoma: a systematic review and meta-analysis of phase II and III randomized controlled trials.2023Cancer Investigation
Efficacy and safety of bevacizumab biosimilars compared with reference biologics in advanced non-small cell lung cancer or metastatic colorectal cancer patients: a network meta-analysis.2022Frontiers in Pharmacology
The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects.2022International Journal of Molecular Sciences
Pneumothorax as a complication of bevacizumab-containing chemotherapy: a systematic review of case reports.2022Cureus
Efficacy and safety of bevacizumab in pretreated metastatic breast cancer: a systematic review and meta-analysis.2022Oncology Research and Treatment
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis.2021Medicine
Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis.2021Frontiers in Medicine
Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis.2021Thoracic Cancer
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials.2021Journal of Clinical Pharmacy and Therapeutics
Bevacizumab treatment of radiation-induced brain necrosis: a systematic review.2021Frontiers in Oncology
Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis.2021Medicine
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis.2021Gynecologic Oncology
Systemic bevacizumab (Avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review.2020The Laryngoscope

Clinical Practice Guidelines